BACKGROUND: Neuroblastoma is a genetically heterogeneous disease, with subsets of tumors demonstrating rearrangements of several genomic regions. Preliminary studies from several groups have identified loss of heterozygosity (LOH) for the long arm of chromosome 14 (14q) in 20-25% of primary neuroblastomas. PROCEDURE: To determine precisely the frequency and extent of 14q deletions, we performed LOH analysis for a large series of primary neuroblastomas using a panel of 11 highly polymorphic markers. RESULTS: LOH was detected in 83 of 372 tumors (22%). Although the majority of tumors with allelic loss demonstrated allelic loss for all informative markers, 13 cases showed LOH for only a portion of 14q. A single consensus region of deletion, which was shared by all tumors with 14q LOH, was defined within 14q23-q32 between D14S588 and the 14q telomere. Allelic loss for 14q was strongly correlated with the presence of 11q LOH (P < 0.001 ) and inversely correlated with MYCN amplification (P= 0.04). CONCLUSIONS: LOH for 14q was evident in all clinical risk groups, indicating that this abnormality may be a universal feature of neuroblastoma tumor development. These findings suggest that a tumor suppressor gene involved in the initiation or progression of neuroblastoma is located within distal 14q.
BACKGROUND:Neuroblastoma is a genetically heterogeneous disease, with subsets of tumors demonstrating rearrangements of several genomic regions. Preliminary studies from several groups have identified loss of heterozygosity (LOH) for the long arm of chromosome 14 (14q) in 20-25% of primary neuroblastomas. PROCEDURE: To determine precisely the frequency and extent of 14q deletions, we performed LOH analysis for a large series of primary neuroblastomas using a panel of 11 highly polymorphic markers. RESULTS: LOH was detected in 83 of 372 tumors (22%). Although the majority of tumors with allelic loss demonstrated allelic loss for all informative markers, 13 cases showed LOH for only a portion of 14q. A single consensus region of deletion, which was shared by all tumors with 14q LOH, was defined within 14q23-q32 between D14S588 and the 14q telomere. Allelic loss for 14q was strongly correlated with the presence of 11q LOH (P < 0.001 ) and inversely correlated with MYCN amplification (P= 0.04). CONCLUSIONS: LOH for 14q was evident in all clinical risk groups, indicating that this abnormality may be a universal feature of neuroblastoma tumor development. These findings suggest that a tumor suppressor gene involved in the initiation or progression of neuroblastoma is located within distal 14q.
Authors: Ruey-Jen Lin; You-Chin Lin; Jeremy Chen; Huan-Hsien Kuo; Yuan-Yan Chen; Mitchell B Diccianni; Wendy B London; Chih-Hao Chang; Alice L Yu Journal: Cancer Res Date: 2010-08-30 Impact factor: 12.701
Authors: Eva Villamón; Marta Piqueras; Carlos Mackintosh; Javier Alonso; Enrique de Alava; Samuel Navarro; Rosa Noguera Journal: Virchows Arch Date: 2008-06-24 Impact factor: 4.064
Authors: Samuel L Volchenboum; Cheng Li; Shuli Li; Edward F Attiyeh; C Patrick Reynolds; John M Maris; A Thomas Look; Rani E George Journal: Cancer Res Date: 2009-05-12 Impact factor: 12.701
Authors: C-H Gattolliat; L Thomas; S A Ciafrè; G Meurice; G Le Teuff; B Job; C Richon; V Combaret; P Dessen; D Valteau-Couanet; E May; P Busson; S Douc-Rasy; J Bénard Journal: Br J Cancer Date: 2011-10-04 Impact factor: 7.640